For the year ending 2025-12-31, TECX had $113,044K increase in cash & cash equivalents over the period. -$60,286K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -74,151 |
| Depreciation and amortization expense | 1,375 |
| Stock-based compensation expense | 10,497 |
| Loss on sale of property and equipment | -153 |
| Reduction in the carrying amount of the operating right-of-use assets | 2,118 |
| Change in fair value of safe liabilities | 0 |
| Prepaid expenses and other current assets | -2,644 |
| Othernon-currentassets | -17 |
| Accounts payable | 116 |
| Accrued expenses and other current liabilities | -552 |
| Operating lease liabilities | -2,295 |
| Net cash used in operating activities | -60,078 |
| Purchase of property and equipment | 208 |
| Proceeds from the sale of property and equipment | 70 |
| Net cash used in investing activities | -138 |
| Proceeds from the private placement, net of offering costs of 11,928 | 173,098 |
| Proceeds from the subscription agreement, net of offering costs of 2,000 | 0 |
| Cash acquired in connection with the merger, net of transaction costs of 7,412 | 0 |
| Proceeds from exercise of stock options | 1,231 |
| Payments for employee taxes related to net share settlement of equity awards | 17 |
| Payment of deferred offering costs | -468 |
| Repayment of finance lease obligations | 489 |
| Net cash provided by financing activities | 173,355 |
| Effect of exchange rate changes on cash and cash equivalents | -95 |
| Net increase in cash and cash equivalents and restricted cash | 113,044 |
| Cash and cash equivalents and restricted cash as of beginning of period | 141,826 |
| Cash and cash equivalents and restricted cash as of end of period | 254,870 |
Tectonic Therapeutic, Inc. (TECX)
Tectonic Therapeutic, Inc. (TECX)